Page 4 - Gland Pharma

Fosun plans to sell of India's $3.8 billion drug maker Gland Pharma

Fosun Pharma, a listed arm of Chinese conglomerate Fosun International Ltd., has been working with an adviser as it informally gauges interest in its controlling stake in Gland, the people said

Gland Pharma to acquire French firm Cenexi Group for Rs 1,000 crore

Will fund transaction from internal accruals

Fosun reportedly planning sale of India's $3.6 billion Gland Pharma

Fosun Pharma, a listed arm of Chinese conglomerate Fosun International Ltd., has been working with an adviser as it informally gauges interest in its controlling stake in Gland

Uncertainty on revenue growth, margin outlook hits Gland Pharma stock

The injectable manufacturing company expects the margin pressure to persist due to cost pressures and negative operating leverage.

Gland Pharma plunges 13%, hits 52-week low on disappointing Q2 results

Earnings before interest, taxes, depreciation, and amortization (EBITDA) margin contracted 150 bps to 33 per cent from 38 per cent in a year ago quarter.

Gland Pharma's Q2 net dips 20.14% to Rs 241.24 cr; India revenue down 42%

Gland Pharma Ltd on Wednesday reported a 20.14 per cent decline in consolidated net profit at Rs 241.24 crore for the second quarter ended September 30, on lower sales and higher expenses. The company had posted a consolidated net profit of Rs 302.08 crore in the same period last fiscal, Gland Pharma said in a regulatory filing. The consolidated revenue from operations during the period under review were at Rs 1,044.4 crore, as against Rs 1,080.47 crore in the year-ago period, it added. Total expenses were higher at Rs 785.95 crore, as compared to Rs 731 crore in the same period a year ago, the company said. Gland Pharma said revenue from its core markets of US, Europe, Canada and Australia grew by 3 per cent to Rs 747.5 crore in the second quarter, as against Rs 722.5 crore in the corresponding period last fiscal. However, India revenue was down 42 per cent at Rs 72.6 crore, as compared to Rs 125.8 crore in the year-ago quarter, while the same for the 'rest of the world' market w

Here's why Mehul Kothari recommends buying Gland Pharma, Indian Oil

According to the technical analyst from Anand Rathi, Gland Pharma can rally to Rs 2,350, while IOC can spurt to Rs 83.

Stocks to watch: Titan, Dr Reddy's, Nelco, IOC, GIC Housing, Torrent Pharma

Stocks to watch today: Titan plans to add 20 to 30 Tanishq stores over two to three years in the Middle East and North America; Nelco inked pact with Intelsat to provide inflight connectivity services

Gland Pharma faces a revenue growth hurdle in FY23; stock falls

The low margin syringes business was impacted by supply chain challenges and shutdown of two manufacturing lines in the domestic market

Gland Pharma slips 10%, hits 52-week low on disappointing Q1 results

Q1 profit after tax tumbled 35 per cent YoY and 20 per cent QoQ to Rs 229 crore, due to lower operational income

Sensex up 630 pts, Nifty atop 16,500; ONGC, RIL, Infy, TCS top contributors

Stock market live updates: At 7:25 AM, the SGX Nifty Futures quoted at 16,512 levels, indicating a gap-up of 172 odd-points.

Gland Pharma rides high on valuation comfort, strong growth prospects

Target prices post brokerage upgrades point to more upsides

Gland Pharma advances 9% on heavy volumes; stock hits 9-week high

At 09:15 AM; around 5.42 million equity shares, representing 3.3 per cent of total equity of Gland Pharma, changed hands on the BSE

Gland Pharma Q3 net profit rises 34% at Rs 273 cr

Gland Pharma on Friday posted a 34 per cent increase in its consolidated profit after tax at Rs 273 crore for the third quarter ended December 31, 2021, riding on robust sales across various markets. The Hyderabad-based drug maker had reported a profit after tax (PAT) of Rs 204 crore in the corresponding period of the previous fiscal. Revenue from operations rose to Rs 1,063 crore in the October-December period of the current fiscal as against Rs 859 crore in the same period of 2020-21 fiscal, Gland Pharma said in a regulatory filing. "While our key market US grew by 23 per cent during the quarter, our focus on geographical diversification is showing robust results with a y-o-y growth of 88 per cent in the Rest of the World markets during the quarter," Gland Pharma MD & CEO Srinivas Sadu noted. In alignment with strategic priorities, the company has completed four complex injectable filings and a total of 18 ANDA filings during the quarter, he added. "We are starting this new year

Gland Pharma gets tentative nod from USFDA for generic Sugammadex injection

Drug firm Gland Pharma on Friday said it has received a tentative nod from the US health regulator for generic Sugammadex injection, which is indicated for reversing the effects of the muscle relaxants rocuronium bromide and vecuronium bromide given to patients during surgery. The company "has received tentative approval from the United States Food and Drug Administration (USFDA) for Sugammadex injection, 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) single-dose vial...", Gland Pharma said in a regulatory filing. The product is the generic version of Merck Sharp & Dohme Corp's Bridion injection, 100 mg/mL, it added. The company will launch the product through its marketing partner on receipt of final approval, Gland Pharma said. According to IQVIA, the Sugammadex injection, 200 mg/2 mL and 500 mg/5 mL single-dose vial had US sales of about USD 615 million for 12 months ended April 2021, it added. Sugammadex injection is used to reverse the effects of the muscle relaxants ...

Gland Pharma shares rally over 9%; at 52-week high after Q1 earnings

Shares of Gland Pharma on Thursday jumped over 9 per cent after the company reported an 11.83 per cent increase in its consolidated net profit for the quarter ended June 30, 2021.

Gland Pharma shares rally nearly 8%; at 52-week high after Q1 earnings

Shares of Gland Pharma on Thursday jumped nearly 8 per cent after the company reported an 11.83 per cent increase in its consolidated net profit for the quarter ended June 30, 2021

Gland Pharma rallies 8% on strong revenue growth in June quarter

Gland Pharma said the growth in revenue was contributed from a mix of launch of new products and volume growth in existing products

Gland Pharma Q1 consolidated net profit up 12% to Rs 350.7 crore

Drug firm Gland Pharma on Wednesday reported an 11.83 percent increase in its consolidated net profit to Rs 350.7 crore for the quarter ended June 30, 2021, on account of robust sales in all markets.

Retail investors miss rally in Gland Pharma; stock up 118% over IPO price

At the time of its IPO, retail investors bid for only 24 per cent or 0.24 times of the shares set aside for them